Study: New Drug Lowers Blood Triglycerides by Up to 45 Percent - Sarmad

A recent medical study showed that a new experimental drug helped lower blood triglyceride levels by 39% to 45% compared with a placebo after 12 weeks of treatment, paving the way for the development of new therapeutic options for people with high triglycerides.

The New England Journal of Medicine reported that the clinical trial, named “TIDAL-TIME 78,” included 236 participants and tested an experimental drug known as MAR001.

The study was led by a research team headed by Dr. Michelle O’Donoghue from Brigham and Women’s Hospital, part of the Mass General Brigham system in the United States, in collaboration with the Timi Research Group, which specializes in cardiovascular diseases.

The results showed that the drug reduced triglyceride levels by 39.1% at a dose of 300 mg, by 40.5% at a dose of 450 mg, and by 45.3% at a dose of 900 mg, compared with the placebo, after 12 weeks of treatment.

The new drug works by inhibiting a protein known as “Angiopoietin-like protein 4,” which is involved in regulating body fat levels. Inhibiting this protein helps activate an enzyme responsible for breaking down triglycerides, thereby lowering their levels in the blood.

Study results showed that side effects among participants who received the drug were no more common than those recorded in the placebo group. Additionally, no signs of worsening blood sugar control were observed during the follow-up period, which lasted 24 weeks.

These results are significant because elevated triglycerides, especially when reaching very high levels, increase the risk of pancreatitis and are associated with cardiovascular disease risks.

This study underscores the importance of modern medical research in developing treatments that target the body’s fat-regulating mechanisms, which may contribute in the future to improving patient care and reducing complications associated with high triglycerides.